William Aird: What Does a Complete History and Physical Really Mean?
William Aird, Professor of Medicine at Harvard Medical School, shared a post on LinkedIn։
“WHAT IS A ‘COMPLETE‘ HISTORY AND PHYSICAL?
I caught myself in clinic recently asking yet another patient whether they smoked and how much alcohol they drank.
Neither answer was particularly relevant to the hematologic problem I was evaluating.
But I realized I would have felt strangely uncomfortable not asking.
It made me think about how much of the traditional history and physical we perform because we were taught that this is what a complete H and P contains.
Social history: smoking and alcohol.
Family history: cancer, heart disease, diabetes, and an expanding cast of relatives.
Physical examination: heart, lungs, abdomen, extremities.
Sometimes these are enormously important.
Smoking matters when evaluating erythrocytosis.
Alcohol matters in macrocytosis or thrombocytopenia.
A family history can completely redirect the evaluation of an unexplained cytopenia.
And of course there are plenty of hematologic problems where lymph nodes, spleen, skin, or cardiopulmonary examination matter.
But should I auscultate the lungs of every asymptomatic patient who comes to see me for iron deficiency?
Do I need to know that their cousin had prostate cancer?
Every question and every examination maneuver has a cost: time, attention, sometimes intrusion, and occasionally false-positive findings.
Maybe a good history and physical shouldn’t be defined by how much we include.
Maybe it should be defined by how thoughtfully we choose what to include.”
Other posts featuring William Aird on Hemostasis Today.
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs